CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net income	$ 800.7	$ 718.9
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	29.2	28.1
Amortization	96.1	66.6
Deferred income taxes	(43.4)	(106.6)
Impairment charges	17.4	2.1
Change in value of contingent consideration	33.0	19.0
Gain on sale of business	(37.5)	0.0
Share-based compensation expense	146.5	128.8
Share-based employee benefit plan expense	9.0	7.7
Derivative instruments	21.3	(7.0)
Other, net	(2.3)	0.6
Change in current assets and liabilities, excluding the effect of acquisitions:
Accounts receivable	23.1	(59.5)
Inventory	(25.6)	7.3
Other operating assets	38.6	(26.4)
Accounts payable and other operating liabilities	(130.3)	59.2
Income tax payable	(2.8)	15.8
Deferred revenue	1.9	1.9
Net cash provided by operating activities	974.9	856.5
Cash flows from investing activities:
Proceeds from sales of marketable securities available for sale	313.9	1,079.8
Purchases of marketable securities available for sale	(285.4)	(678.8)
Capital expenditures	(59.6)	(42.3)
Proceeds from sales of investment securities	0.3	6.8
Purchases of investment securities	(79.4)	(27.5)
Net cash (used in) provided by investing activities	(110.2)	338.0
Cash flows from financing activities:
Payment for treasury shares	(1,410.0)	(1,012.6)
Proceeds from short-term borrowing	0.0	90.0
Principal repayments on short-term borrowing	0.0	(189.6)
Net proceeds from common equity put options	2.8	5.2
Net proceeds from share-based compensation arrangements	62.4	114.4
Excess tax benefit from share-based compensation arrangements	25.1	84.5
Net cash used in financing activities	(1,319.7)	(908.1)
Effect of currency rate changes on cash and cash equivalents	20.2	(40.3)
Net (decrease) increase in cash and cash equivalents	(434.8)	246.1
Cash and cash equivalents at beginning of period	4,880.3	4,121.6
Cash and cash equivalents at end of period	4,445.5	4,367.7
Supplemental schedule of non-cash investing and financing activity:
Change in net unrealized loss on marketable securities available for sale	381.8	77.1
Investment in Human Longevity, Inc. common stock	39.6	0.0
Supplemental disclosure of cash flow information:
Interest paid	200.9	50.2
Income taxes paid	$ 102.1	$ 106.7